Table 3.
Summary of recent metabolomics studies in the field NAFLD
Reference | Tissue | Platform | Decreased or increased metabolites in the patients compared to the control group |
---|---|---|---|
Puri P (2009) | Plasma | HPTLC GCFID LCMS |
palmitoleic, oleic acids dihomo gamma-linolenic (20:3n6) acids, Triacylglycerols, palmitoleic acid to palmitic acid (16:0) ratio Linoleic acid |
García-Canaveras JC(2011) | liver | UPLCESIQTOFMS | hypoxanthineglutamine, γ-glutamyl-dipeptides creatinine, GCDCA , TCDCA L-glutamyl-L-lysine, Lleucyl-L-proline, glutamate, |
Kalhan SC(2011) | plasma | UPLCESITQMS GCMS |
carnitine, butyrylcarnitine (C5), glutamyl dipeptides, glutamyl valine, glutamyl leucine, glutamyl phenylalanine and glutamyl tyrosine, methylbutyrylcarnitine, glycocholate, taurocholate, glycochenodeoxycholate, Mannose and lactate glutathione, long-chain fatty acids and cysteine-glutathione |
JonathanBarr(2010) | serum | UPLC/MS | lysophosphatidylcholine (LPC),deoxycholic acid bile acids (BAs), sphingomyelin: (SM 36:3), (d18:2/16:0), (d18:2/14:0), (d18:1/18:0), (d18:1/16:0), (d18:1/12:0), and (d18:0/16:0) Creatine |
Red color: increased metabolite
Blue color: decreased metabolite